Drug
Osimertinib
Osimertinib: highest development phase Approved, developed by AstraZeneca, Eli Lilly, Wayshine Biopharm, Inc.. 4 trial records tracked on RxWires.
- Highest phase
- Approved
- Developer
- AstraZeneca, Eli Lilly, Wayshine Biopharm, Inc.
Trials
| Drug | Phase | Indication |
|---|---|---|
| TAGRISSO | Approved | |
| Osimertinib NCT03909334 | Phase 2 | Non Small Cell Lung Cancer |
| Osimertinib NCT05546866 | Phase 2 | Non-small Cell Lung Cancer |
| Osimertinib (Tagrisso®) NCT07206498 | Phase 1/2 | Non Small Cell Lung Cancer (NSCLC) |
Latest
No recent events.
Follow Osimertinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.